CTLA4 enhances the osteogenic differentiation of allogeneic human mesenchymal stem cells in a model of immune activation.
Braz J Med Biol Res
; 48(7): 629-36, 2015 Jul.
Article
em En
| MEDLINE
| ID: mdl-26017342
Allogeneic mesenchymal stem cells (allo-MSCs) have recently garnered increasing interest for their broad clinical therapy applications. Despite this, many studies have shown that allo-MSCs are associated with a high rate of graft rejection unless immunosuppressive therapy is administered to control allo-immune responses. Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) is a co-inhibitory molecule expressed on T cells that mediates the inhibition of T-cell function. Here, we investigated the osteogenic differentiation potency of allo-MSCs in an activated immune system that mimics the in vivo allo-MSC grafting microenvironment and explored the immunomodulatory role of the helper T cell receptor CTLA4 in this process. We found that MSC osteogenic differentiation was inhibited in the presence of the activated immune response and that overexpression of CTLA4 in allo-MSCs suppressed the immune response and promoted osteogenic differentiation. Our results support the application of CTLA4-overexpressing allo-MSCs in bone tissue engineering.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Osteogênese
/
Linfócitos T
/
Terapia de Imunossupressão
/
Transplante de Células-Tronco Mesenquimais
/
Células-Tronco Mesenquimais
/
Antígeno CTLA-4
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
Braz J Med Biol Res
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
China
País de publicação:
Brasil